One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1016/j.annonc.2021.10.139
Copy DOI Journal: Annals of Oncology |  Publication Date: Dec 1, 2021 |
 Citations: 17 |  License type: publisher-specific-oa |
Affiliation: Sendai Kousei Hospital, Seoul National University, University of Florence, MSD (United States), Institute of Cancer Research of Montpellier, Inserm, University of Montpellier, Regional Clinical Hospital No 4, Soroka Medical Center, National Taiwan University, Florida Hospital Cancer Institute120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
